bioRxiv : the preprint server for biology · 2026
Tumor-derived SAA1-TLR4 signaling drives tumor-to-muscle communication in pancreatic cancer cachexia.
СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guarnaccia Gabriele, Massenet Jimmy, Cecchini Alessandra, Guarnaccia Elena, Silvestri Beatrice, Nicoletti Chiara, Barajas Jesus R, Sala David, Teneche Marcos G, Li Brightany, Caputo Luca, Stamenkovic Cedomir, Moreno Tatiana M, Murad Rabi, Delaware Shawn, Mayer Daphne, Zhang Yijuan, Gupta Priyanka, Colas Alexandre R, Vasciaveo Alessandro, Kumsta Caroline, Adams Peter D, Wang Will, Gargioli Cesare, Cosimo Commisso, Puri Pier Lorenzo, Sacco Alessandra
Аннотация
Cancer cachexia limits treatment tolerance and survival in pancreatic ductal adenocarcinoma (PDAC), yet the tumor-derived signals driving tissue dysfunction remain poorly understood. Here, we identify serum amyloid A1 (SAA1) as a mediator of tumor- to-host communication acting through Toll-like receptor 4 (TLR4). Tumor-derived SAA1 was elevated in human PDAC and in a mouse PDAC model and disrupted both myofiber and muscle stem cell (MuSC) homeostasis. Genetic reduction of tumor-derived SAA1 uncoupled tumor progression from host wasting, preserving muscle mass and function and prolonging survival without affecting primary tumor growth. Mechanistically, SAA1-TLR4 signaling drove multicellular remodeling of the skeletal muscle microenvironment. Therapeutic TLR4 inhibition after cachexia onset restored muscle mass, function and MuSC abundance and prolonged survival independently of tumor growth. Conservation of SAA1-TLR4 signaling in human skeletal muscle identifies a therapeutically actionable tumor-host pathway and demonstrates that host deterioration can be targeted independently of tumor progression.